Abstract

The drug-resistant tuberculosis strains that are on track to become the world's deadliest infections are responsible for one-fourth of the deaths caused by antimicrobial resistance.[2] the prevalence of MDR-TB is between 3% & 50% among re-treatment cases. There is a rise in the number of instances of multidrug-resistant tuberculosis in the present day. Understanding the connection between diabetes & MDR-TB is becoming increasingly important as the prevalence of MDR-TB rises worldwide. Diabetes & tuberculosis (TB) have been studied together for a long time. Patients incur greater financial costs due to TB-diabetes mellitus comorbidities & delayed diagnosis & treatment. The sooner these diseases are diagnosed, the more likely they are to be treated successfully. Material and Methods: This study was a hospital based cross sectional research conducted in the Department of respiratory medicine, TMMC & RC, MORADABAD among 160 patients who were sputum smear positive & those who meet our inclusion & exclusion criteria was taken in study group. The aim of the research was to analyse the occurrence of DM with Rifampicin Resistance in patient of Pulmonary Tuberculosis. Result: It was a hospital a cross-sectional research conducted in the Department of pulmonary medicine, TMMC & RC, MORADABAD among 160 patients. Maximum participants were between the ages of 51 & 60 (26.25%), then 41 & 50 (22.50%), & the youngest were between the ages of 16 & 20 (6.88%) & 31 & 40 (10%). Male participants accounted for 69.4% of the total H/O ATT intake was reported among 10% of the study subjects in this study. Out of 160 subjects, 68.1% live in rural area while 31.9% reside in urban location. diabetes mellitus was revealed in 27.50% of the subjects. Most common clinical symptom was cough (96.9%) followed by fever (78.7%) & sputum (72.5%). Mean HbA1c among the study subjects was 6.54±2.34. Out of 43 diabetic subjects with positive AFB outcome; 27, 9 & 7 subjects had diabetes since <1 year, 1-5 year & >5 year respectively. Samples were found to be resistance in 9.09%, 2.59% & 90.91%, 97.41% of the subjects with & without diabetes mellitus respectively. Mean HbA1c level in CBNAAT resistant & sensitive outcome was 7.77±2.53 & 6.48±2.27 respectively with statistically significant difference. Conclusion: Our findings suggest a link between diabetes and rifampin resistance, so we recommend integrating diabetes surveillance into TB programs, especially in changing epidemiological contexts. Quantifying the disparities in TB diagnostic findings is also needed to provide a global research setting where study results may be appropriately compared.

Description